Respiratory Syncytial Virus (RSV) Infections drugs in development, 2023
The Respiratory Syncytial Virus (RSV) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Respiratory Syncytial Virus (RSV) Infections. Buy the report here.The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued products.GlobalData tracks 184 drugs in development for Respiratory Syncytial Virus (RSV) Infections by 144 companies/universities/institutes. The top development phase for Respiratory Syncytial Virus (RSV) Infections is preclinical with 92 drugs in that stage. The Respiratory Syncytial Virus (RSV) Infections pipeline has 159 drugs in development by companies and 25 by universities/ institutes. Some of the companies in the Respiratory Syncytial Virus (RSV) Infections pipeline products market are: National Institute of Allergy and Infectious Diseases, Pfizer and Sanofi.The key targets in the Respiratory Syncytial Virus (RSV) Infections pipeline products market include Respiratory Syncytial Virus Fusion Protein (RSV F Protein), Respiratory Syncytial Virus RNA Directed RNA Polymerase L (Large Structural Protein or Replicase or Transcriptase or mRNA Guanylyltransferase or GDP Polyribonucleotidyltransferase or L or EC 2.7.7.48 or EC 2.1.1.56 or EC 2.7.7.88), and Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G).The key mechanisms of action in the Respiratory Syncytial Virus (RSV) Infections pipeline product include Respiratory Syncytial Virus Fusion Protein (RSV F Protein) Inhibitor with 23 drugs in Pre-Registration. The Respiratory Syncytial Virus (RSV) Infections pipeline products include nine routes of administration with the top ROA being Oral and 22 key molecule types in the Respiratory Syncytial Virus (RSV) Infections pipeline products market including Small Molecule, and Subunit Vaccine.Respiratory Syncytial Virus (RSV) Infections overviewRespiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice.For a complete picture of Respiratory Syncytial Virus (RSV) Infections's pipeline drug market, buy the report here.
GlobalData tracks 184 drugs in development for Respiratory Syncytial Virus (RSV) Infections by 144 companies/universities/institutes. The top development phase for Respiratory Syncytial Virus (RSV) Infections is preclinical, with 92 drugs in that stage.
What's Your Reaction?
